IMV moves COVID-19 vaccine to clinical trials

By The Science Advisory Board staff writers

May 22, 2020 -- Clinical-stage biopharmaceutical company IMV has announced that it is moving forward with a vaccine against the novel coronavirus to test in clinical trials.

The company first studied immunogenic and antibody responses to 23 peptide epitopes in preclinical trials before selecting multiple peptides for its vaccine candidate, DPX-COVID-19. The vaccine is intended to work through multiple mechanisms to prevent infection and inhibit the virus from entering cells.

Vaccine development remains on schedule, and IMV plans to conduct a phase I clinical study this summer. The company is also performing vaccination-challenge preclinical assays in animal models with the intent to publish results later this year.

Big data analysis of images may aid vaccine development
A new pipeline that combines high-dimensional microscopy with big data analysis to gain molecular insights in T-cell biology and vaccine development was...
AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...
Inovio vaccine proves potent against SARS-CoV-2 in preclinical trials
Inovio announced that preclinical data for its INO-4800 vaccine candidate were published in Nature Communications on May 20. The results suggesting...
Bharat, TJU partnering on COVID-19 vaccine
Bharat Biotech and Thomas Jefferson University (TJU) of Philadelphia have signed a deal to develop a new vaccine for COVID-19.
Moderna lays out plan for mRNA-1273 vaccine
Moderna released interim clinical data about mRNA-1273, its vaccine candidate against SARS-CoV-2, from the phase I study led by the U.S. National Institute...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter